학술논문
Third Report of the Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on Diabetes and Cancer: Summary of the Results of a Questionnaire Survey of Oncologists and Diabetologists / 糖尿病と癌に関する合同委員会報告 第3報―がん主治医・糖尿病専門医へのアンケート調査より―
Document Type
Journal Article
Author
Akihito Tsuji; Akiko Tamakoshi; Atsushi Goto; Eiji Hara; Hiroshi Noto; Hirotaka Watada; Kazutoshi Fujibayashi; Keitaro Matsuo; Ken Ohashi; Kohjiro Ueki; Koshi Mimori; Makoto Kodaira; Manami Inoue; Masanobu Oshima; Mitsuhiko Noda; Rimei Nishimura; Shin Takahashi; Tatsuya Ioka; Yoshinori Murakami; Yuko Tanabe; 三森 功士; 井上 真奈美; 井岡 達也; 公平 誠; 原 英二; 大島 正伸; 大橋 健; 後藤 温; 村上 善則; 松尾 恵太郎; 植木 浩二郎; 玉腰 暁子; 田辺 裕子; 綿田 裕孝; 能登 洋; 藤林 和俊; 西村 理明; 辻 晃仁; 野田 光彦; 高橋 信
Source
糖尿病 / Journal of the Japan Diabetes Society. 2023, 66(9):705
Subject
Language
Japanese
ISSN
0021-437X
1881-588X
1881-588X
Abstract
The Japan Diabetes Society (JDS) and the Japan Cancer Association (JCA) launched a joint committee and published their "First Joint Committee Report on Diabetes and Cancer" in 2013, compiling recommendations for physicians and healthcare providers as well as for the general population. In 2016, the "Second Joint Committee Report on Diabetes and Cancer" summarized the current evidence on glycemic control and cancer risk in patients with diabetes. The current "Third Joint Committee Report on Diabetes and Cancer", for which the joint committee also enlisted the assistance of the Japanese Society of Clinical Oncology (JSCO) and the Japanese Society of Medical Oncology (JSMO), reports on the results from the questionnaire survey, "Diabetes Management in Patients Receiving Cancer Therapy, " which targeted oncologists responsible for cancer management and diabetologists in charge of glycemic control in cancer patients. The results of the current survey demonstrated that there is a general consensus among oncologists and diabetologists with regard to the need for guidelines on glycemic control goals, the relevance of glycemic control, and glycemic control during cancer therapy in cancer patients.